Skip to main content
Equibles
NUVB logo

NUVB · Nuvation Bio Inc. · Earnings Call Transcripts & Audio

Track NUVB — free

Use NUVB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NUVB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.26 -0.02 (-0.32%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.21B
Shares
351.12M

Nuvation Bio Inc. Earnings Call Transcripts

Quarterly earnings calls for Nuvation Bio Inc. (NUVB), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $3.08M −$53.24M '25 Q1 25-05-28 ▲236.8% $4.83M −$59.01M '25 Q2 25-08-07 ▲1704.7% $13.12M −$55.79M '25 Q3 25-11-03 ▲633.1% $41.87M −$36.59M '25 Q4 26-03-02 ▲2598.7% $83.23M $5.40M '26 Q1 26-05-04 LATEST ▲555.6% $31.69M −$62.84M '26 Q2 26-08-06
Conference
Investor event
2026-09-09
Nuvation Bio Inc. (NUVB) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript
Confident tone Ibtrozi (Deptrosi) commercial launch and revenue growth Durability and chronic-disease launch dynamic ROS1 testing rates and education
Revenue
$31.69M
▲ 555.6% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Nuvation Bio Inc. (NUVB) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-19
Nuvation Bio Inc. (NUVB) May 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-04
Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript
Confident tone Iptrozy commercial launch and patient dynamics Future guidance and reporting Clinical data, durability and safety profile
Revenue
$83.23M
▲ 2598.7% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript
Confident tone IBTROZI Commercial Launch Pipeline Termination (NUV-1511) ROS1 / TRKb Mechanism
Revenue
$41.87M*
▲ 633.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript
Confident tone IBTROZI U.S. Commercial Launch Efficacy and Durability Data Pipeline and Partnerships
Revenue
$13.12M
▲ 1704.7% YoY
Diluted EPS
$-0.16
Gross margin
74.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Nuvation Bio Inc. (NUVB) Q2 2025 Earnings Call Transcript
Confident tone Efficacy and safety profile Pipeline and safusitinib (FAFU) Regulatory discussions
Revenue
$4.83M
▲ 236.8% YoY
Diluted EPS
$-0.17
Gross margin
46.7%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2025-06-12
Nuvation Bio Inc. (NUVB) June 2025 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q1
2025-05-28
Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript
Confident tone Taletrectinib PDUFA and approval Competitive positioning vs. repotrectinib/crizotinib Safusidenib pipeline asset
Revenue
$3.08M
Diluted EPS
$-0.16
Gross margin
32.1%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–10 of 10 earnings calls
Key facts CIK 1811063 CUSIP 67080N101 13F (30d) 135 filings 135 filers Visit website Investor relations